Protective Immunity Against Respiratory Tract Challenge with Yersinia Pestis in Mice Immunized with an Adenovirus-based Vaccine Vector Expressing V Antigen
Overview
Authors
Affiliations
The aerosol form of the bacterium Yersinia pestis causes the pneumonic plague, a rapidly fatal disease. At present, no plague vaccines are available for use in the United States. One candidate for the development of a subunit vaccine is the Y. pestis virulence (V) antigen, a protein that mediates the function of the Yersinia outer protein virulence factors and suppresses inflammatory responses in the host. On the basis of the knowledge that adenovirus (Ad) gene-transfer vectors act as adjuvants in eliciting host immunity against the transgene they carry, we tested the hypothesis that a single administration of a replication-defective Ad gene-transfer vector encoding the Y. pestis V antigen (AdsecV) could stimulate strong protective immune responses without a requirement for repeat administration. AdsecV elicited specific T cell responses and high IgG titers in serum within 2 weeks after a single intramuscular immunization. Importantly, the mice were protected from a lethal intranasal challenge of Y. pestis CO92 from 4 weeks up to 6 months after immunization with a single intramuscular dose of AdsecV. These observations suggest that an Ad gene-transfer vector expressing V antigen is a candidate for development of an effective anti-plague vaccine.
Progress on the research and development of plague vaccines with a call to action.
Williamson E, Kilgore P, Hendrix E, Neil B, Sha J, Chopra A NPJ Vaccines. 2024; 9(1):162.
PMID: 39242587 PMC: 11379892. DOI: 10.1038/s41541-024-00958-1.
Gupta A, Narayan B, Kumar S, Verma S Front Immunol. 2020; 11:988.
PMID: 32595634 PMC: 7303293. DOI: 10.3389/fimmu.2020.00988.
Demeure C, Dussurget O, Mas Fiol G, Le Guern A, Savin C, Pizarro-Cerda J Genes Immun. 2019; 20(5):357-370.
PMID: 30940874 PMC: 6760536. DOI: 10.1038/s41435-019-0065-0.
Plague Vaccine Development: Current Research and Future Trends.
Verma S, Tuteja U Front Immunol. 2016; 7:602.
PMID: 28018363 PMC: 5155008. DOI: 10.3389/fimmu.2016.00602.
Plague Vaccines: Status and Future.
Sun W Adv Exp Med Biol. 2016; 918:313-360.
PMID: 27722869 PMC: 6559729. DOI: 10.1007/978-94-024-0890-4_12.